SRP product and index pages do not print CAS, UNII, PubChem CID, molecular formula, sequence, termini (free acid vs N-acetyl / C-amide), salt form, or a public COA. Identity below is taken only from opened public registries and from primary papers that name KPV, α-MSH[11-13], MSH 11-13, or Lys-Pro-Val.

One-sentence identity: KPV is the C-terminal tripeptide of α-MSH (residues 11–13), Lys-Pro-Val / H-Lys-Pro-Val-OH. Opened PubChem CID 125672 titles the free-acid record “Msh (11-13)” and prints CAS 67727-97-3, formula C16H30N4O4, and MW 342.43 g/mol. It is not α-MSH, not ACTH, not melanotan II, not bremelanotide / PT-141, not afamelanotide, not K(D)PT, not GHK-Cu, and not the SRP GHK-Cu + KPV 50/10 mg blend. This is a defined tripeptide sequence on opened registries, not a copper complex and not a 13-residue POMC hormone.

Opened SRP product page (16 August 2026): title “KPV 10 mg Inflammation Research Peptide Vial”. Category line: Recovery / Inflammation Research. Subhead: “KPV 10mg Research Peptide.” Bullets: Vial Size 10 mg; Purity ≥99%; COA available; Made in the USA; lyophilized research peptide; third-party tested; laboratory and research applications only. Description: supplied for controlled laboratory evaluation of KPV within Recovery / Inflammation Research studies. Research material: KPV. Listed strength: 10 mg Vial. Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Price printed $60.00. Availability: “5 in stock (can be backordered).” Shipping-box fields: Weight 1 lbs; Dimensions 1 × .5 × 2 in. Reviews (0). Price, stock, and shipping-box fields are vendor listings, not chemistry.

Not printed on the opened product page and therefore not claimed as SRP-verified: Lys-Pro-Val sequence; free acid vs Ac-amide termini; CAS; UNII; CID; salt/counter-ion; a public COA file; a published 10 mg laboratory dose.

Opened SRP index card (compound-research-guides, 16 August 2026): “KPV (10 mg Vial)” under Recovery; tag Evidence profile (not “Dedicated evidence guide”); evidence tier Preclinical evidence; field Inflammation research. Overview: “KPV is the C-terminal tripeptide Lys-Pro-Val derived from alpha-melanocyte-stimulating hormone and studied for anti-inflammatory activity.” Mechanism: laboratory effects on inflammatory transcription and epithelial immune responses, including NF-κB; “a definitive standalone receptor mechanism remains under study.” Evidence: most from cell and animal models, including intestinal and skin-related research; controlled human efficacy and safety evidence limited. Quality note: distinguish KPV-specific data from full-length α-MSH or other melanocortin agonists.

Opened dedicated-guide URL http://simpleresearchpeptides.com/research-compound-directory/kpv-research-guide/ returned HTTP 404 on 16 August 2026. This page is written for that missing standalone listing. The live GHK-Cu + KPV Research Guide already treats KPV as component 2 (CID 125672; CAS 67727-97-3; no UNII; no IUPHAR ligand; 0 KPV NCT). Component papers remain component papers. Combination untested as a unit.

Form-chaos that must not be collapsed. CID 125672 is the free-acid tripeptide (H-Lys-Pro-Val-OH). Depositor synonyms also include “H-Lys-Pro-Val-OH AcOH” / acetate salt. Acetate salt ≠ a different sequence, but it is a different solid form (related CID 90474670). Hiltz & Lipton 1989 (PMID 2550304) tested α-MSH[11-13] and named lysine-proline-valine as the antipyretic message sequence; that abstract does not print N-acetyl / C-amide termini. Hiltz, Catania & Lipton 1991 (PMID 1788140) tested Ac-α-MSH(11-13)-NH2 and D-amino-acid analogs — an N-acetyl, C-amide tripeptide, not automatically CID 125672. Europe PMC chemical list for Hiltz 1990 (PMID 2284205) includes N-acetyllysyl-prolyl-valinamide, registry number 57899-96-4, alongside MSH (11-13) CAS 67727-97-3. That is a different CAS for the acetylated amide (CID 6453546). Do not collapse 57899-96-4 into 67727-97-3. Dalmasso 2008 (PMID 18061177) names KPV (Lys-Pro-Val); Europe PMC chemicals for that paper list MSH (11-13) CAS 67727-97-3. This page does not assume SRP “KPV 10 mg” is the acetylated amide, the free acid, or any 1989/1991/2008 lot. Confirm termini on a COA.

Critical identity point. CID 125672 is the free-acid all-L tripeptide H-Lys-Pro-Val-OH. Hiltz, Catania & Lipton 1991 (PMID 1788140) tested Ac-α-MSH(11-13)-NH2 and D-amino-acid analogs — an N-acetyl, C-amide tripeptide, not automatically CID 125672. Dalmasso 2008 (PMID 18061177) names KPV as Lys-Pro-Val. This page does not assume the SRP “KPV 10 mg” lot is the free acid, the acetate salt, or the 1989/1991 acetylated amide. Confirm termini, stereochemistry, and salt on a COA / LC-MS.

Registry chaos that must not be collapsed.

• PubChem depositor synonyms include “H-LYS-PRO-VAL-OH ACETATE SALT” and “H-Lys-Pro-Val-OH AcOH”. Those sit on the free-acid CID. They are nomenclature noise, not proof of the SRP counter-ion.
• NCATS LYS-PRO-VAL is a substring collision against longer POMC / ACTH / afamelanotide sequences that contain the three residues. Those UNIIs are not KPV. No KPV UNII is used on this page.
• openFDA CAS 67727-97-3 → ondansetron ANDA209389 is a string collision. Unused as KPV identity.
• ClinicalTrials.gov Lys-Pro-Val hits (opened examples: NCT02477644 PAOLA-1 olaparib; NCT04874688 CHAIN nutrition; NCT03017768 acute tryptophan depletion; NCT05214872 CKD) are lexical, not KPV-peptide trials. Unused. Do not invent a KPV NCT.
• IUPHAR has ligands for α-MSH, ACTH, MT-II, bremelanotide, and afamelanotide. It has no KPV ligand.

Not printed on SRP pages and therefore not claimed as SRP-verified: sequence, CAS, UNII, CID, termini, salt, or a public COA file. The product page prints a “COA available” bullet but does not display a public COA. SRP itself is a research-material listing, not a Hiltz-lab or Dalmasso-lab lot.

KPV is three residues at the C-terminus of the 13-residue POMC peptide α-MSH. Catalog “inflammation / recovery” language does not convert a research tripeptide into Vyleesi, Scenesse, melanotan II, or a copper-peptide complex. This page is standalone KPV 10 mg only. The live GHK-Cu + KPV blend guide already states combination untested as a unit and 0 blend NCT. Do not merge streams.

Opened primary papers support a C-terminal α-MSH-fragment working model. It is not a treatment claim. It was not generated with an SRP 10 mg vial. Observed means a measurement in an opened paper. Proposed means a hypothesis. Class / adjacent means distinction biology. Not shown means the opened papers did not establish it for a research-market lot.

Not shown for an SRP 10 mg vial: a completed receptor assignment; human PK; a ClinicalTrials.gov KPV record; proof that the SRP lot is free-acid CID 125672 rather than Ac-KPV-NH2; PepT1 or MC1 data generated with that lot; human IBD or dermatitis efficacy; chemical identity of termini on a public COA.

Label every row. KPV ≠ α-MSH ≠ melanotan II ≠ PT-141 ≠ GHK-Cu ≠ the 50/10 vial. Historical language is not a completed therapeutic program. Nanomolar cell-culture concentrations and oral drinking-water exposure in mice are study conditions, not instructions for an SRP 10 mg research vial, and they are not claims that research-grade material works in people.

Read the “what it did not show” column. Published study designs are historical facts from those papers. They are not a protocol. Nanomolar cell-culture concentrations and oral drinking-water exposure in mice are study conditions, not instructions for an SRP 10 mg research vial.

A. Opened KPV / α-MSH(11-13) papers

B. Human / NCT snapshot

Empty of KPV trials. ClinicalTrials.gov returned 0 studies for KPV as term or intervention. Do not invent an NCT. Lys-Pro-Val lexical hits are unused (NCT02477644 PAOLA-1 olaparib; NCT04874688 CHAIN nutrition; NCT03017768 acute tryptophan depletion; NCT05214872 CKD). Those are not KPV-peptide trials.

C. Blend-specific snapshot

None opened as a unit. The live GHK-Cu + KPV blend guide already states combination untested and 0 blend NCT. This page does not re-open GHK-Cu fibroblast or rat-chamber papers as KPV evidence.

These are gaps. Treating any of them as settled is incorrect.

• No human clinical evidence for KPV as a drug. 0 KPV NCTs. Opened work is mouse dermatitis/edema, keratinocyte signaling, and mouse colitis.
• No proof the SRP vial is CID 125672 free acid. Sequence, termini, CAS, UNII, and a public COA were not printed. Hiltz 1991 used Ac-amide analogs.
• No FDA-approved therapeutic use. openFDA KPV: NOT_FOUND. CAS collision with ondansetron is unused.
• No IUPHAR ligand and no UNII. Receptor assignment is incomplete. NCATS LYS-PRO-VAL hits are parent-hormone records.
• PepT1-mediated uptake is a working model (Dalmasso 2008), not shown for an SRP lot, for skin fibroblasts, or in the presence of GHK-Cu.
• MC1 independence is incomplete, not absent (Kannengiesser 2008). Elliott 2004 found no cAMP in keratinocytes.
• α-MSH / melanotan / PT-141 / afamelanotide findings are not KPV. K(D)PT is a different tripeptide.
• The 50/10 blend is a different listing. Combination untested. Do not merge GHK-Cu evidence into KPV claims.
• No opened PK, bioavailability, chronic toxicology, carcinogenicity, or reproductive-tox package for an SRP 10 mg vial. Historical nanomolar concentrations and mouse drinking-water exposure are not instructions.

Each card is a single opened record. Reviews are secondary. Historical concentrations and mouse drinking-water exposure are study conditions, not instructions. No KPV NCT is attached because ClinicalTrials.gov returned 0 studies.

KPV / α-MSH(11-13) is an investigational laboratory research tripeptide. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions.

Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

Laboratory identity is the first practical issue. Opened papers and PubChem CID 125672 describe the free-acid all-L tripeptide Lys-Pro-Val / H-Lys-Pro-Val-OH (title “Msh (11-13)”; CAS 67727-97-3; C16H30N4O4; 342.43 g/mol; InChIKey YSPZCHGIWAQVKQ-AVGNSLFASA-N; 3 defined stereocenters). ChEBI CHEBI:160254 is the same tripeptide. A research vial labeled “KPV” is not chemically identified until sequence, termini (free acid vs N-acetyl / C-amide), stereochemistry, and salt are confirmed analytically.

Form-chaos that must not be collapsed.

• CID 125672 is the free-acid tripeptide. Depositor synonyms also include “H-Lys-Pro-Val-OH AcOH” / acetate salt. Acetate salt ≠ a different sequence, but it is a different solid form.
• Related acetate-salt CID 90474670 (L-lysyl-L-prolyl-L-valine acetate; C18H34N4O6; 402.5 g/mol; parent CID 125672) is a salt, not a second peptide.
• Hiltz & Lipton 1989 (PMID 2550304) tested α-MSH[11-13] and named lysine-proline-valine as the antipyretic message sequence. That abstract does not print N-acetyl / C-amide termini.
• Hiltz, Catania & Lipton 1991 (PMID 1788140) tested Ac-α-MSH(11-13)-NH2 and D-amino-acid analogs — an N-acetyl, C-amide tripeptide, not automatically CID 125672.
• Europe PMC chemical list for Hiltz 1990 (PMID 2284205) includes N-acetyllysyl-prolyl-valinamide, registry number 57899-96-4, alongside MSH (11-13) CAS 67727-97-3. That is a different CAS for the acetylated amide. Do not collapse 57899-96-4 into 67727-97-3.
• Ac-amide analog CID 6453546 (title N-acetyllysyl-prolyl-valinamide; CAS 57899-96-4; MeSH Ac-Lys-Pro-ValNH2; C16H32N4O3; 328.45 g/mol) is not CID 125672.
• Dalmasso 2008 (PMID 18061177) names KPV (Lys-Pro-Val). Europe PMC chemicals for that paper list MSH (11-13) CAS 67727-97-3.
• This page does not assume SRP “KPV 10 mg” is the acetylated amide, the free acid, or any 1989/1991/2008 lot. Confirm termini on a COA / LC-MS.

Registry chaos that must not be collapsed.

• No UNII on CID 125672. NCATS LYS-PRO-VAL hits are longer POMC / melanocortin proteins that contain a KPV triplet (afamelanotide, corticotropins, seractide, tiplimotide, nonapeptide-1, CTCE-0214). Those UNIIs are not KPV.
• IUPHAR has no KPV ligand. Receptor assignment is incomplete. Parent-hormone ligands (α-MSH 1320; ACTH 1331 / corticotropin 3633; MT-II 1323; bremelanotide 10408; afamelanotide 1324; MC1 target 282) are distinction only.
• openFDA string 67727-97-3 hitting ondansetron ANDA209389 is a false-positive lexical match, not a KPV NDA.
• PubChem depositor synonyms include ACTH-(11-13). A three-residue fragment is not corticotropin.
• Human POMC UniProt P01189 / COLI_HUMAN, 267 aa; α-MSH feature residues 138–150 = SYSMEHFRWGKPV. Precursor mapping is distinction, not a KPV drug record.
• ClinicalTrials.gov Lys-Pro-Val lexical hits (NCT02477644, NCT04874688, NCT03017768, NCT05214872) are not KPV peptide trials and are unused.

Confirm sequence, termini, stereochemistry, and salt by LC-MS before treating a vial as the literature article. Independently sourced research peptides are not established as equivalent to the Hiltz 1989 / 1991 lots, the Dalmasso 2008 drinking-water material, or CID 125672 free acid. Historical nanomolar cell-culture concentrations and mouse drinking-water exposure are study conditions from those papers. They are not a reconstitution scheme and they are not a use guide for an SRP 10 mg research vial.

Biological inference has the same problem. The opened record is mouse irritant / edema / colitis models, keratinocyte signaling without a cAMP response in HaCaT / NHK, a PepT1 working model, incomplete MC1 independence, in-vitro antimicrobial activity, and a secondary review that distinguishes KPV from K(D)PT. ClinicalTrials.gov returned 0 studies. That is not a completed human anti-inflammatory program and is not evidence for research-market vials.

The live GHK-Cu + KPV Research Guide already states combination untested as a unit and 0 blend NCT. Do not cite a GHK-Cu fibroblast or rat-chamber paper as KPV evidence. Do not merge this standalone 10 mg listing with the 50/10 mixture. The live GHK-Cu dedicated guide keeps GHK-Cu as glycyl-L-histidyl-L-lysine copper complex with no FDA-approved injectable GHK-Cu drug — retained, not contradicted.

Sources actually opened for the locked draft. Do not add PMIDs or NCTs that are not on the allowed list. ClinicalTrials.gov returned 0 studies for KPV; no KPV NCT is listed. Reviews are secondary. Component papers remain component papers.

Allowed PMID list used on this page (KPV / α-MSH(11-13) named — primary preclinical; do not cite as human efficacy or as GHK-Cu / blend efficacy): 2550304 (Hiltz 1989); 2284205 (Hiltz 1990); 1788140 (Hiltz 1991 Ac-amide analogs); 12750433 (Getting 2003 peritonitis / MC dissection); 10670585 (Cutuli 2000 in-vitro antimicrobial); 15102092 (Elliott 2004 keratinocytes); 18061177 (Dalmasso 2008 PepT1 / colitis); 18092346 (Kannengiesser 2008 colitis / MC1Re/e). Secondary / distinction: 17934097 (Luger & Brzoska 2007; KPV vs K(D)PT). NCT: none for KPV. Opened PMC: PMC2431115 (Dalmasso 2008; abstract used); PMC2095288 (Luger & Brzoska 2007; abstract + full text used for distinction). No other PMIDs were added. No NCT was invented.

Product links are research materials, not treatment recommendations. Opened SRP page: KPV 10 mg Inflammation Research Peptide Vial; category Recovery / Inflammation Research (store taxonomy, not a clinical indication). Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Sequence, CAS, UNII, CID, termini, and a public COA were not printed on the fetched page. Do not confuse with α-MSH (IUPHAR 1320), ACTH / corticotropin (IUPHAR 1331 / 3633), melanotan II (IUPHAR 1323), bremelanotide / PT-141 / Vyleesi (IUPHAR 10408; FDA 2019), afamelanotide (IUPHAR 1324), K(D)PT / KdPT, Ac-α-MSH(11-13)-NH2 (Hiltz 1991; CAS 57899-96-4), GHK-Cu 100 mg standalone, free GHK / prezatide without copper, or the GHK-Cu + KPV 50/10 blend.